Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DAPTOMYCIN Cause Therapy non-responder? 66 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 66 reports of Therapy non-responder have been filed in association with DAPTOMYCIN (daptomycin). This represents 0.7% of all adverse event reports for DAPTOMYCIN.

66
Reports of Therapy non-responder with DAPTOMYCIN
0.7%
of all DAPTOMYCIN reports
5
Deaths
39
Hospitalizations

How Dangerous Is Therapy non-responder From DAPTOMYCIN?

Of the 66 reports, 5 (7.6%) resulted in death, 39 (59.1%) required hospitalization, and 2 (3.0%) were considered life-threatening.

Is Therapy non-responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DAPTOMYCIN. However, 66 reports have been filed with the FAERS database.

What Other Side Effects Does DAPTOMYCIN Cause?

Off label use (791) Drug ineffective (658) Product use in unapproved indication (654) Eosinophilic pneumonia (575) Acute kidney injury (501) Blood creatine phosphokinase increased (461) Pyrexia (447) Eosinophilia (405) Rhabdomyolysis (383) Drug reaction with eosinophilia and systemic symptoms (307)

What Other Drugs Cause Therapy non-responder?

ETANERCEPT (3,472) APREMILAST (3,360) METHOTREXATE (2,965) RITUXIMAB (2,731) ADALIMUMAB (2,595) PREDNISONE (2,563) TREPROSTINIL (2,289) INFLIXIMAB (2,122) TOCILIZUMAB (1,775) HYDROXYCHLOROQUINE (1,699)

Which DAPTOMYCIN Alternatives Have Lower Therapy non-responder Risk?

DAPTOMYCIN vs DARATUMUMAB DAPTOMYCIN vs DARATUMUMAB\HYALURONIDASE-FIHJ DAPTOMYCIN vs DARBEPOETIN ALFA DAPTOMYCIN vs DARIDOREXANT DAPTOMYCIN vs DARIFENACIN HYDROBROMIDE

Related Pages

DAPTOMYCIN Full Profile All Therapy non-responder Reports All Drugs Causing Therapy non-responder DAPTOMYCIN Demographics